HYDERGINE
LOE ApproachingNDAORALTABLET
Approved
Dec 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDERGINE is an oral small-molecule tablet approved in 1977 by Novartis under NDA status. The drug's specific mechanism of action, indications, and patient population are not publicly detailed in available data. It represents a legacy product from the pre-modern pharmaceutical era with established clinical utility.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting declining market presence and potential team restructuring or consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE, HYDERGINE represents a legacy product with limited career growth potential. Professionals considering roles on this product should expect focus on managed decline, generic strategy, and potential divestment rather than expansion and innovation.
Brand ManagerField Sales
Worked on HYDERGINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.